

Bern, January 2024

SAKK / Astellas GU-Oncology Award

The future of oncology is fueled by efforts of outstanding researchers and their research teams. Innovative preclinical and clinical research projects will continuously improve our knowledge in oncology and address emerging challenges.

Research is a continuous professional and personal commitment, therefore, SAKK's and Astellas' intent is to motivate and honor young researcher on this important journey.

To further preclinical and clinical oncology research in Switzerland, SAKK and Astellas team up to confer a Swiss GU-Oncology Award. A researcher will be awarded as representative of a research group or project for an outstanding scientific and/or clinical achievement documented by a scientific publication (published paper or accepted manuscript in a peer-reviewed journal).

The focus of the SAKK / Astellas GU-Oncology Award lies on potential tangible improvements for patient management and outcomes in the treatment of genitourinary cancers.

The award is endowed with CHF 30'000.- and should encourage the continuation of research activities. Hence the awarded sum is to be used for ongoing and future research within the respective research group or project.

Call for Applications

Prior to your application, please carefully read the applicable Award Rules. In case of questions, please do not hesitate to contact the SAKK.

Please send your application until April 30th, 2024.

Full applications must be sent via e-mail to events@sakk.ch and shall include:

- Curriculum Vitae of the candidate
- Letter of support, which shall emphasize and highlight the scientific and/or clinical achievement of the candidate relevant to the SAKK / Astellas GU-Oncology Award
- Relevant publication or manuscript (published paper or accepted manuscript in a peer-reviewed journal)
- Publication list of the candidate relevant to this award
- If applicable, any other relevant information or documentation

Selection Process

An independent jury of experts, elected by the SAKK president, will evaluate the submitted applications based on (i) alignment with the scope of the award, (ii) scientific quality, (iii) national and (iv) international (future) scientific and/or clinical impact, and (v) innovative potential and novelty.

For more details, please view the applicable Award Rules.

Award Announcement

The winner of the SAKK / Astellas GU-Oncology Award 2024 will be awarded during the SAKK semi-annual meeting on 26th June 2024.

Award Rules

Astellas Pharma AG distributes the SAKK / Astellas GU-Oncology Award with the support of the Swiss Group of Clinical Cancer Research (SAKK) and the support of an independent jury at the SAKK semi-annual meeting on June 26th, 2024. The award will be conferred to an eligible candidate, who may be a surgeon, physician, or scientist, active in genitourinary oncology research within Switzerland. The research project must have been accepted or published in a peer-reviewed journal within the past 24 months (until application deadline). The winner will be awarded as representative of a research group or project for outstanding scientific and/or clinical achievements within the thematic focus of the SAKK / Astellas GU-Oncology Award 2024.

Eligible Candidates

1. An eligible candidate must fulfill the following criteria:
 - a) Researcher – this may be a surgeon, physician, or scientists – currently active in preclinical or clinical urogenital cancer research in Switzerland. The minimum requirement is a research activity in Switzerland from January 1st to December 31st, 2024
 - b) Principal investigator, research group head or researcher with a leading role in a research project
 - c) Under 45 years of age as of December 31st, 2024

Valid Applications

2. Candidates can nominate themselves
3. The candidate must submit the complete candidature and documentation to the coordinating person at the SAKK until April 30th, 2024:
 - a) Recent Curriculum Vitae of the candidate
 - b) Letter of support written, dated, and signed. The letter of support shall emphasize and highlight the scientific and/or clinical achievements of the candidate and the respective research group or project relevant to the SAKK / Astellas GU-Oncology Award 2024
 - c) Publication list relevant to the SAKK / Astellas GU-Oncology Award
 - (i) Publications may be primary research or review articles
 - (ii) The candidate must be an author on all publications
 - (iii) Publications must have been published in the period 2019-2024 in a peer-reviewed journal or must be accepted for publication in a peer-reviewed journal
 - d) Any other information if applicable

4. The application must be submitted in English
5. Resubmission of applications that did not win in past editions are permitted as long as eligibility criteria are met
6. Applications must be sent via e-mail to the Swiss Group of Clinical Cancer Research (SAKK), events@sakk.ch

Evaluation of Applications

7. An independent jury composed of 2-3 Swiss experts and the SAKK President. The SAKK President chairs the jury. He may delegate a member of the SAKK Board to chair the jury (for example if conflict of interest occurs). Employees of Astellas must not be part of the jury
8. Jury members must not evaluate applications of their own institution or university
9. Project proposals will be evaluated only if they are deemed to be eligible and feasible
10. The independent jury will evaluate the submitted valid applications on a scale from 1-10 (1 = worst, 10 = best) for each of the following criteria:
 - a) Alignment with scope of award, i.e. potential tangible improvements for patient management and outcomes in the treatment of genitourinary tumors
 - b) Scientific quality
 - c) National (future) scientific and/or clinical impact of research achievements
 - d) International (future) scientific and/or clinical impact of research achievements
 - e) Innovative potential and novelty
11. The jury head shall identify the top scoring application, based on calculated mean values for each application
12. The jury elects the winner based on the evaluation scoring. In case different applicants achieve the same scoring, the top scoring applications shall be discussed amongst the jury members. The jury shall elect 1 winner by consensus. In case consensus cannot be reached, the chairman has the final decision
13. The jury is free and independent in its decisions. Its decisions are final and not subject to appeal
14. If additional scientific expertise is needed the SAKK president can request written evaluations from additional reviewers
15. The SAKK and Astellas Pharma AG may waive the award of the SAKK / Astellas GU-Oncology Award if the jury considers none of the submitted applications worthy of support

Awarding

16. At least 2 weeks before the award ceremony, all applicants will be notified by the head of the jury and the winner shall be confidentially informed by the head of the jury about winning the SAKK / Astellas GU-Oncology Award
17. The winner or, if unable to attend, a representative of the winning research group or project shall present the scientific and/or clinical achievements for which the award is distributed at the SAKK semi-annual meeting on 26th June 2024.
18. After the winner announcement, the SAKK / Astellas GU-Oncology Award shall be distributed officially to the winner by an Astellas employee and the SAKK President

19. Three weeks at most after the ceremony SAKK will transfer the prize money to the winning research group or project

Role of Astellas Pharma AG

20. Astellas Pharma AG is the sole sponsor of the SAKK / Astellas GU-Oncology Award
21. Astellas Pharma AG informs about the SAKK / Astellas GU-Oncology Award on its own website ([SAKK / Astellas GU-Oncology Award | Astellas Pharma Switzerland](#)), describing the award, the candidature process and the selection of the winner
22. Astellas Pharma AG must not be part of the award jury and thus must not evaluate applications
23. Together with the support of the SAKK an employee of Astellas Pharma AG will announce the winner together with the jury head and hand over the award at the SAKK semi-annual meeting on 26th June 2024.